Merck Gross Profit 2010-2024 | MRK
Merck annual/quarterly gross profit history and growth rate from 2010 to 2024. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
- Merck gross profit for the quarter ending March 31, 2024 was $12.235B, a 15.85% increase year-over-year.
- Merck gross profit for the twelve months ending March 31, 2024 was $45.663B, a 8.95% increase year-over-year.
- Merck annual gross profit for 2023 was $43.989B, a 5.06% increase from 2022.
- Merck annual gross profit for 2022 was $41.872B, a 19.37% increase from 2021.
- Merck annual gross profit for 2021 was $35.078B, a 25.73% increase from 2020.
Merck Annual Gross Profit
(Millions of US $) |
| 2023 |
$43,989 |
| 2022 |
$41,872 |
| 2021 |
$35,078 |
| 2020 |
$27,900 |
| 2019 |
$27,105 |
| 2018 |
$28,785 |
| 2017 |
$27,210 |
| 2016 |
$25,777 |
| 2015 |
$24,564 |
| 2014 |
$25,469 |
| 2013 |
$27,079 |
| 2012 |
$30,821 |
| 2011 |
$31,176 |
| 2010 |
$27,591 |
| 2009 |
$18,409 |
Merck Quarterly Gross Profit
(Millions of US $) |
| 2024-03-31 |
$12,235 |
| 2023-12-31 |
$10,719 |
| 2023-09-30 |
$11,698 |
| 2023-06-30 |
$11,011 |
| 2023-03-31 |
$10,561 |
| 2022-12-31 |
$9,949 |
| 2022-09-30 |
$11,025 |
| 2022-06-30 |
$10,377 |
| 2022-03-31 |
$10,521 |
| 2021-12-31 |
$9,648 |
| 2021-09-30 |
$9,704 |
| 2021-06-30 |
$8,298 |
| 2021-03-31 |
$7,428 |
| 2020-12-31 |
$4,633 |
| 2020-09-30 |
$7,916 |
| 2020-06-30 |
$6,606 |
| 2020-03-31 |
$8,745 |
| 2019-12-31 |
$2,575 |
| 2019-09-30 |
$8,407 |
| 2019-06-30 |
$8,359 |
| 2019-03-31 |
$7,764 |
| 2018-12-31 |
$7,709 |
| 2018-09-30 |
$7,175 |
| 2018-06-30 |
$7,048 |
| 2018-03-31 |
$6,853 |
| 2017-12-31 |
$6,993 |
| 2017-09-30 |
$7,018 |
| 2017-06-30 |
$6,814 |
| 2017-03-31 |
$6,385 |
| 2016-12-31 |
$6,644 |
| 2016-09-30 |
$7,127 |
| 2016-06-30 |
$6,266 |
| 2016-03-31 |
$5,740 |
| 2015-12-31 |
$6,365 |
| 2015-09-30 |
$6,312 |
| 2015-06-30 |
$6,031 |
| 2015-03-31 |
$5,856 |
| 2014-12-31 |
$6,733 |
| 2014-09-30 |
$6,334 |
| 2014-06-30 |
$6,041 |
| 2014-03-31 |
$6,361 |
| 2013-12-31 |
$6,713 |
| 2013-09-30 |
$6,928 |
| 2013-06-30 |
$6,726 |
| 2013-03-31 |
$6,712 |
| 2012-12-31 |
$7,577 |
| 2012-09-30 |
$7,351 |
| 2012-06-30 |
$8,199 |
| 2012-03-31 |
$7,694 |
| 2011-12-31 |
$8,118 |
| 2011-09-30 |
$7,670 |
| 2011-06-30 |
$7,867 |
| 2011-03-31 |
$7,521 |
| 2010-12-31 |
$7,654 |
| 2010-09-30 |
$6,934 |
| 2010-06-30 |
$6,797 |
| 2010-03-31 |
$6,206 |
| 2009-12-31 |
$5,192 |
| 2009-09-30 |
$4,619 |
| 2009-06-30 |
$4,546 |
| 2009-03-31 |
$4,051 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$331.772B |
$60.115B |
|
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
|
